224 related articles for article (PubMed ID: 22487715)
1. [From drug cost to drug price: steps and decisional processes].
Bruyninckx M; Nourissier C
Presse Med; 2012 May; 41 Suppl 1():S40-3. PubMed ID: 22487715
[No Abstract] [Full Text] [Related]
2. Multifaceted roles of ultra-rare and rare disease patients/parents in drug discovery.
Wood J; Sames L; Moore A; Ekins S
Drug Discov Today; 2013 Nov; 18(21-22):1043-51. PubMed ID: 23968993
[TBL] [Abstract][Full Text] [Related]
3. Medicines for rare (orphan) diseases: an enquiry and proposal for tax-incentives.
John JE
Drug Discov Today; 2011 Dec; 16(23-24):999-1000. PubMed ID: 22020052
[No Abstract] [Full Text] [Related]
4. Outrageous prices of orphan drugs: a call for collaboration.
Luzzatto L; Hyry HI; Schieppati A; Costa E; Simoens S; Schaefer F; Roos JCP; Merlini G; Kääriäinen H; Garattini S; Hollak CE; Remuzzi G;
Lancet; 2018 Sep; 392(10149):791-794. PubMed ID: 30037734
[No Abstract] [Full Text] [Related]
5. Orphan economics: the downside of supplyside pharmacology.
Samson K
Ann Neurol; 2008 Sep; 64(3):A13-6. PubMed ID: 18825669
[No Abstract] [Full Text] [Related]
6. HHS defends expanded 340B drug discounts.
Lee J
Mod Healthc; 2014 Jun; 44(24):9. PubMed ID: 25137989
[No Abstract] [Full Text] [Related]
7. [Not Available].
Med Sci (Paris); 2016 Apr; 32 Spec No 1():29-33. PubMed ID: 27137859
[No Abstract] [Full Text] [Related]
8. New models for pharmaceutical innovation in low-income countries.
Ardal C; Iversen JH; Myhr K
Tidsskr Nor Laegeforen; 2011 Oct; 131(20):2016-8. PubMed ID: 22016131
[No Abstract] [Full Text] [Related]
9. Birgitte Volck.
Nat Rev Drug Discov; 2017 May; 16(6):378-379. PubMed ID: 28559559
[No Abstract] [Full Text] [Related]
10. Rare lung disease and orphan drug development.
Spagnolo P; du Bois RM; Cottin V
Lancet Respir Med; 2013 Aug; 1(6):479-87. PubMed ID: 24429246
[TBL] [Abstract][Full Text] [Related]
11. New drugs carry hefty price tags. Makers of leading-edge orphan products asked to cut prices, take smaller profits.
Lee J
Mod Healthc; 2013 Oct; 43(40):14. PubMed ID: 24340725
[No Abstract] [Full Text] [Related]
12. [Orphan drugs: drugs for rare diseases].
Schenk M
Dtsch Med Wochenschr; 2010 May; 135(18):p17. PubMed ID: 20455291
[No Abstract] [Full Text] [Related]
13. A comparative study of European rare disease and orphan drug markets.
Denis A; Mergaert L; Fostier C; Cleemput I; Simoens S
Health Policy; 2010 Oct; 97(2-3):173-9. PubMed ID: 20800761
[TBL] [Abstract][Full Text] [Related]
14. Proposed 'grant-and-access' program with price caps could stimulate development of drugs for very rare diseases.
Valverde AM; Reed SD; Schulman KA
Health Aff (Millwood); 2012 Nov; 31(11):2528-35. PubMed ID: 23129684
[TBL] [Abstract][Full Text] [Related]
15. Optimal drug pricing, limited use conditions and stratified net benefits for Markov models of disease progression.
Zaric GS
Health Econ; 2008 Nov; 17(11):1277-94. PubMed ID: 18186544
[TBL] [Abstract][Full Text] [Related]
16. [Cohorts and registers: Which public/private partnerships to choose?].
Jouan-Flahault C; Landais P; Thomas R; Parker S; Genevaz D
Presse Med; 2012 May; 41 Suppl 1():S15-9. PubMed ID: 22464892
[No Abstract] [Full Text] [Related]
17. The balancing act of orphan drug pricing.
The Lancet
Lancet; 2017 Dec; 390(10113):2606. PubMed ID: 29256396
[No Abstract] [Full Text] [Related]
18. Companies look for profit in orphan drugs.
Thompson CA
Am J Health Syst Pharm; 2010 Nov; 67(22):1892, 1895-6. PubMed ID: 21048203
[No Abstract] [Full Text] [Related]
19. Lowering Part D drug costs without direct CMS negotiations.
Sipkoff M
Manag Care; 2009 Sep; 18(9):11-2. PubMed ID: 19886203
[No Abstract] [Full Text] [Related]
20. Rare diseases and effective treatments: are we delivering?
Luzzatto L; Hollak CE; Cox TM; Schieppati A; Licht C; Kääriäinen H; Merlini G; Schaefer F; Simoens S; Pani L; Garattini S; Remuzzi G
Lancet; 2015 Feb; 385(9970):750-2. PubMed ID: 25752159
[No Abstract] [Full Text] [Related]
[Next] [New Search]
